001     130346
005     20240228143426.0
024 7 _ |a 10.1080/2162402X.2016.1240859
|2 doi
024 7 _ |a pmid:28123878
|2 pmid
024 7 _ |a pmc:PMC5215250
|2 pmc
024 7 _ |a 2162-4011
|2 ISSN
024 7 _ |a 2162-402X
|2 ISSN
037 _ _ |a DKFZ-2017-05425
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Poschke, Isabel
|0 P:(DE-He78)e9c55f46b4b06cf835834ee7e3e00db8
|b 0
|e First author
|u dkfz
245 _ _ |a Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma.
260 _ _ |a Austin, Tex.
|c 2016
|b Landes Bioscience
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1524815580_6707
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The devastating prognosis of patients with resectable pancreatic ductal adenocarcinoma (PDA) presents an urgent need for the development of therapeutic strategies targeting disseminated tumor cells. Until now, T-cell therapy has been scarcely pursued in PDA, due to the prevailing view that it represents a poorly immunogenic tumor.We systematically analyzed T-cell infiltrates in tumor biopsies from 127 patients with resectable PDA by means of immunohistochemistry, flow cytometry, T-cell receptor (TCR) deep-sequencing and functional analysis of in vitro expanded T-cell cultures. Parallel studies were performed on tumor-infiltrating lymphocytes (TIL) from 44 patients with metastatic melanoma.Prominent T-cell infiltrates, as well as tertiary lymphoid structures harboring proliferating T-cells, were detected in the vast majority of biopsies from PDA patients. The notion that the tumor is a site of local T-cell expansion was strengthened by TCR deep-sequencing, revealing that the T-cell repertoire in the tumor is dominated by highly frequent CDR3 sequences that can be up to 10,000-fold enriched in tumor as compared to peripheral blood. In fact, TCR repertoire composition in PDA resembled that in melanoma. Moreover, in vitro expansion of TILs was equally efficient for PDA and melanoma, resulting in T-cell cultures displaying HLA class I-restricted reactivity against autologous tumor cells.The tumor-infiltrating T-cell response in PDA shows striking similarity to that in melanoma, where adoptive T-cell therapy has significant therapeutic impact. Our findings indicate that T-cell-based therapies may be used to counter disease recurrence in patients with resectable PDA.
536 _ _ |a 317 - Translational cancer research (POF3-317)
|0 G:(DE-HGF)POF3-317
|c POF3-317
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Faryna, Marta
|b 1
700 1 _ |a Bergmann, Frank
|b 2
700 1 _ |a Flossdorf, Michael
|0 P:(DE-He78)fd2afb52af9b43e5bb535b58dfed2e33
|b 3
|u dkfz
700 1 _ |a Lauenstein, Claudia
|0 P:(DE-He78)67614eacdbe6fe4404a46d2f8d01ac52
|b 4
|u dkfz
700 1 _ |a Hermes, Jennifer
|0 P:(DE-He78)0b2362bf6f508111903e365937ce9fca
|b 5
|u dkfz
700 1 _ |a Hinz, Ulf
|b 6
700 1 _ |a Hank, Thomas
|b 7
700 1 _ |a Ehrenberg, Roland
|b 8
700 1 _ |a Volkmar, Michael
|0 P:(DE-He78)792fd96345efded9a78c902105479a68
|b 9
|u dkfz
700 1 _ |a Loewer, Martin
|b 10
700 1 _ |a Glimm, Hanno
|b 11
700 1 _ |a Hackert, Thilo
|b 12
700 1 _ |a Sprick, Martin
|0 P:(DE-He78)0f44fcb0b05507b0a20b175f7ba9ed1c
|b 13
|u dkfz
700 1 _ |a Höfer, Thomas
|0 P:(DE-He78)9dbe272aaadbdc810ab0bb291eae428e
|b 14
|u dkfz
700 1 _ |a Trumpp, Andreas
|0 P:(DE-He78)732f4fbcddb0042251aa759a2e74d3b2
|b 15
|u dkfz
700 1 _ |a Halama, Niels
|b 16
700 1 _ |a Hassel, Jessica C
|b 17
700 1 _ |a Strobel, Oliver
|0 P:(DE-He78)72d8cf00da99b760892d11c3a0a446bd
|b 18
|u dkfz
700 1 _ |a Büchler, Markus
|b 19
700 1 _ |a Sahin, Ugur
|b 20
700 1 _ |a Offringa, Rienk
|0 P:(DE-He78)81ae96953d6149e4307057d71a190019
|b 21
|e Last author
|u dkfz
773 _ _ |a 10.1080/2162402X.2016.1240859
|g Vol. 5, no. 12, p. e1240859 -
|0 PERI:(DE-600)2645309-5
|n 12
|p e1240859 -
|t OncoImmunology
|v 5
|y 2016
|x 2162-402X
909 C O |o oai:inrepo02.dkfz.de:130346
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)e9c55f46b4b06cf835834ee7e3e00db8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)fd2afb52af9b43e5bb535b58dfed2e33
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)67614eacdbe6fe4404a46d2f8d01ac52
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)0b2362bf6f508111903e365937ce9fca
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)792fd96345efded9a78c902105479a68
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)0f44fcb0b05507b0a20b175f7ba9ed1c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)9dbe272aaadbdc810ab0bb291eae428e
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)732f4fbcddb0042251aa759a2e74d3b2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 18
|6 P:(DE-He78)72d8cf00da99b760892d11c3a0a446bd
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 21
|6 P:(DE-He78)81ae96953d6149e4307057d71a190019
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-317
|2 G:(DE-HGF)POF3-300
|v Translational cancer research
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2016
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ONCOIMMUNOLOGY : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ONCOIMMUNOLOGY : 2015
920 1 _ |0 I:(DE-He78)G180-20160331
|k G180
|l Molekulare Grundlagen Gastrointestinaler Tumoren
|x 0
920 1 _ |0 I:(DE-He78)B086-20160331
|k B086
|l Theoretische Systembiologie
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)G180-20160331
980 _ _ |a I:(DE-He78)B086-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21